Eiko Lifesciences has allotted 1,50,000 equity shares to promoter group entity Lenus Finvest following a warrant conversion. The allotment at Rs 55 per share lifts the promoter's stake to 18.18%, signaling increased backing from the core holding group.
Eiko Lifesciences Completes Promoter Warrant Conversion
1,50,000 equity shares were allotted at Rs 55 per share.
Paid-up capital now stands at Rs 14.80 crore across 1,48,00,854 shares.
Reader Takeaway: Promoter stake increases to 18.18% via warrant conversion, providing capital infusion for the company's growth plans.
What just happened
Eiko Lifesciences Limited has finalized the conversion of 1,50,000 warrants held by Lenus Finvest Private Limited into equity shares. The board approved the allotment via circular resolution on October 16, 2026. This follows the payment of the remaining 75% balance of the issue price by the promoter entity.
Why this matters
The transaction signifies a direct cash infusion into the company, as the warrants were issued earlier this year with a 25% upfront payment. The conversion effectively increases the promoter's influence, with Lenus Finvest's shareholding in the company rising from 17.34% to 18.18%. This move reflects promoter confidence in the company's long-term value proposition.
The backstory
The warrants were originally issued on February 24, 2026. At that time, subscribers paid an initial 25% of the total issue price of Rs 55 per share. With this current round, the conversion process for this specific tranche is complete. The company maintains a total face value of Rs 10 per share with a premium of Rs 45 per share.
What to track next
Investors should monitor the status of the remaining 24,95,000 outstanding warrants. As these warrants continue to be converted, they will further alter the company's equity base and potentially provide additional liquidity to the business. Keep a watch on upcoming filings for any further updates on warrant exercise schedules.